CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages

  Antonelli, Alessandro ^a   Bocci, Guido ^a,b   Fallahi, Poupak ^a   La Motta, Concettina ^a   Ferrari, Silvia Martina ^a   Mancusi, Caterina ^a   Fioravanti, Anna ^a   Di Desidero, Teresa ^a   Sartini, Stefania ^a   Corti, Alessandro ^a   Piaggi, Simona ^a   Materazzi, Gabriele ^a   Spinelli, Claudio ^a   Fontanini, Gabriella ^a   Danesi, Romano ^a   Da Settimo, Federico ^a   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLM 3; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898475791     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2321     Document Type: Article

References (36)

1. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg . 2007;392:397-404.
2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol . 2006;13:453-464.
3. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol . 1999;16:64-69.
4. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am . 2008;37:525-538.
5. Wartofsky L. Highlights of the American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid carcinoma: the 2009 revision. Thyroid . 2009;19:1139-1143.
6. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys . 2004;60:1137-1143.
7. Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem . 2012;12: 87-93.
8. Antonelli A, Bocci G, La Motta C, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab . 2011;96:E288-E296.
9. Bocci G, Fioravanti A, La Motta C, et al. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Biochem Pharmacol . 2011;81:1309-1316.
10. Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf) . 2008;69:148-152.
11. Antonelli A, Ferrari SM, Fallahi P, et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol . 2008;159:283-291.
12. Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf) . 2009;70:946-953.
13. Fiore L, Pollina LE, Fontanini G, et al. Cytokine production by anew undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab . 1997;82:4094-4100.
14. Agretti P, De Marco G, De Servi M, et al. Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thyroidassociated ophthalmopathy (TAO) after adipocytic differentiation. Eur J Endocrinol . 2005;152:777-784.
15. Copland JA, Marlow LA, Williams SF, et al. Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases. Thyroid . 2006;16:1293-1302.
16. Christensen L, Blichert-Toft M, Brandt M, et al. Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule. Clin Endocrinol (Oxf) . 2000;53:161-169.
17. Antonelli A, Ferrari SM, Fallahi P, et al. Dysregulation of secretion of CXC -chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor- agonists. Endocr Relat Cancer . 2009;16:1299-1311.
18. Antonelli A, Bocci G, La Motta C, et al. CLM94,a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab . 2012;97:E528-E536.
19. Bocci G, Falcone A, Fioravanti A, Orlandi P, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer . 2008;98:1619-1629.
20. Carlomagno F, Vitagliano D, Guida T, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res . 2002;62:1077-1082.
21. Carlomagno F, Vitagliano D, Guida T, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl) -7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab . 2003;88:1897-1902.
22. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependent T cell activation. J Biol Chem . 1996;271:695-701.
23. La Motta C, Mugnaini L, Sartini S, et al. Derivati a nucleo pirazolo[ 3,4-d]pirimidinici quali inibitori di proteine tirosina chinasi. 2007;RM2007A000480.
24. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab . 2008;93:3106-3116.
25. Shinohara M, Chung YJ, Saji M, Ringel MD. AKT in thyroid tumorigenesis and progression. Endocrinology . 2007;148:942-947.
26. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/Akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab . 2008;93:278-284.
27. Di Desidero T, Fioravanti A, Orlandi P, et al. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. J Clin Endocrinol Metab . 2013;98:E1465-E1473.
28. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci . 2008;121:3853-3857.
29. Lee JJ, Au AY, Foukakis T, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer . 2008;15:801-815.
30. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol . 2007;14:719-729.
31. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther . 2010;9:592-603.
32. Lanzi C, Cassinelli G, Cuccuru G, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci . 2003;60:1449-1459.
33. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor ofKDRtyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res . 2002;62:7284-7290.
34. Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev . 2010; 31:578-599.
35. Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol . 2007; 35:185-197.
36. Antonelli A, Ferri C, Ferrari SM, et al. New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol . 2010;2010: 921682.